EHA 2015

✓

Tuntutan

Masukkan bar carian ini ke laman web anda

CARI EPISOD LEPAS

Cari episod lepas bagi EHA 2015.

EPISOD SEBELUMNYA 🔗

Are CML patients being treated to the correct standard?

6 Ogo 2015

Dr Hoffmann (Ludwig Maximilian University, Munich, Germany) talks to ecancertv at EHA 2015 about a web-based registry to record all newly-diagnosed chronic myeloid leukaemia (CML) patients in 20 European countries or pre-specified regions covering overall 92.5 million inhabitants. The researche ...

00:05:32

Does the patient with myelofibrosis feel better through pacritinib?

6 Ogo 2015

At a press conference at EHA 2015, Dr Mesa (Mayo Clinic Cancer Center, Scottsdale, USA) presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients wi ...

00:04:37

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

6 Ogo 2015

Dr Olga Guryanova (Memorial Sloan Kettering Cancer Center, New York, USA) presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.

00:07:39

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

6 Ogo 2015

Dr Meletios Dimopoulos (National and Kapodistrian University of Athens, Athens, Greece) talks to ecancertv at EHA 2015 about the results of ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone and is the first Phase III study to demonstrate the benefit of dir ...

00:06:43

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia

6 Ogo 2015

Dr Ehninger (University Hospital Dresden, Dresden, Germany) presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.

00:06:30

New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

6 Ogo 2015

Dr Roberts presents the promising results from an early phase trial combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL) at a press conference at EHA 2015.

00:04:41

$Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL$

Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL

6 Ogo 2015

Prof Anton Hagenbeek (University Medical Center Utrecht, Utrecht, Netherlands) talks to ecancertv at EHA 2015 about the results of Dr Andrew Roberts' early phase Ib trial which looked at combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL). ec ...

00:02:18

Overview of innovation in Hodgkin's lymphoma

6 Ogo 2015

Prof Diehl ( Winner of the Jean Bernard Lifetime Achievement Award) talks to ecancertv at EHA 2015 about his amazing work in the field of Hodgkin's lymphoma and the evolution of research and treatment strategies over time. ecancer's filming at EHA has been kindly supported by Amgen through the ...

00:10:35

$Factors influencing response to blinatumomab in relapsed/refractory ALL$

Factors influencing response to blinatumomab in relapsed/refractory ALL

6 Ogo 2015

Prof Max Topp ( Würzburg University Hospital, Würzburg, Germany) talks to ecancertv at EHA 2015 about his research which showed that acute lymphoblastic leukaemia (ALL) patients with low disease burden had lower responses to blinatumomab. Those with higher disease burden could be candidates for ...

00:05:34